Recombinant Vaccine Strain ASFV-G-Δ9GL/ΔUK Produced in the IPKM Cell Line Is Genetically Stable and Efficacious in Inducing Protection in Pigs Challenged with the Virulent African Swine Fever Virus Field Isolate Georgia 2010

Journal Article · 13 April 2024 · Pathogens

DOI: https://doi.org/10.3390/pathogens13040319 · OSTI ID:2471279

Ramirez-Medina, Elizabeth ^[1]; Rai, Ayushi ^[2]; Espinoza, Nallely ^[1]; Spinard, Edward  ^[1]; Silva, Ediane  ^[3]; Burton, Leeanna  ^[3]; Clark, Jason ^[3]; Meyers, Amanda ^[2]; Valladares, Alyssa ^[2]; Velazquez-Salinas, Lauro ^[1]; Gay, Cyril G. ^[4]; Gladue, Douglas P.  ^[1]; Borca, Manuel V. ^[1]

---

1. US Dept. of Agriculture (USDA), Greenport, NY (United States). Agricultural Research Service (ARS), Plum Island Animal Disease Center; US Dept. of Agriculture (USDA), Manhattan, KS (United States). Agricultural Research Service (ARS)
2. US Dept. of Agriculture (USDA), Greenport, NY (United States). Agricultural Research Service (ARS), Plum Island Animal Disease Center; Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN (United States)
3. US Dept. of Agriculture (USDA), Manhattan, KS (United States). Agricultural Research Service (ARS)
4. US Dept. of Agriculture (USDA), Beltsville, MD (United States). Agricultural Research Service (ARS)

We have previously reported that the recombinant African Swine Fever (ASF) vaccine candidate ASFV-G-Δ9GL/ΔUK efficiently induces protection in domestic pigs challenged with the virulent strain Georgia 2010 (ASFV-G). As reported, ASFV-G-Δ9GL/ΔUK induces protection, while intramuscularly (IM), administered at doses of 10⁴ HAD₅₀ or higher, prevents ASF clinical disease in animals infected with the homologous ASFV g strain. Like other recombinant vaccine candidates obtained from ASFV field isolates, ASFV-G-Δ9GL/ΔUK stocks need to be produced in primary cultures of swine macrophages, which constitutes an important limitation in the production of large virus stocks at the industrial level. Here, we describe the development of ASFV-G-Δ9GL/ΔUK stocks using IPKM (Immortalized Porcine Kidney Macrophage) cells, which are derived from swine macrophages. We show that ten successive passages of ASFV-G-Δ9GL/ΔUK in IPKM cells induced small changes in the virus genome. The produced virus, ASFV-G-Δ9GL/ΔUKp10, presented a similar level of replication in swine macrophages cultures to that of the original ASFV-G-Δ9GL/ΔUK (ASFV-G-Δ9GL/ΔUKp0). The protective efficacy of ASFV-G-Δ9GL/ΔUKp10 was evaluated in pigs that were IM-inoculated with either 10⁴ or 10⁶ HAD₅₀ of ASFV-G-Δ9GL/ΔUKp10. While animals inoculated with 10⁴ HAD₅₀ present a partial protection against the experimental infection with the virulent parental virus ASFV-G, those inoculated with 10⁶ HAD₅₀ were completely protected. Therefore, as was just recently reported for another ASF vaccine candidate, ASFV-G-ΔI177L, IPKM cells are an effective alternative to produce stocks for vaccine strains which only grow in swine macrophages.

• Research Organization: Oak Ridge Institute for Science and Education (ORISE), Oak Ridge, TN (United States)
• Sponsoring Organization: USDOE Office of Science (SC)
• Grant/Contract Number: SC0014664
• OSTI ID: 2471279
• Journal Information: Pathogens, Journal Name: Pathogens Journal Issue: 4 Vol. 13; ISSN 2076-0817
• Publisher: MDPICopyright Statement
• Country of Publication: United States
• Language: English